Reference |
---|
Smith M, Teel L, Carvalho H, Melton-Celsa A, O'BRIEN A. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine. 2006;24:4122-9 pubmed
|
Smith M, Carvalho H, Melton-Celsa A, O'BRIEN A. The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect Immun. 2006;74:6992-8 pubmed
|
5405 PB UDEN
Hycult Biotech’s mission and strategy is to advance insight in innate immunity related diseases, for the benefit of individuals and their quality of life.
As a leader within focused fields of immunology and cell biology, we develop products for the life sciences and in accordance with our mission it is our ambition to facilitate the transition of these products from research use into diagnostic testing. Many of our reagents are developed in close cooperation with scientists worldwide. Hycult Biotech has built a strong network with over 40 close scientific collaborations with leading international research institutes. We contribute to numerous projects and as a result, can continuously offer early access to an expanding range of innovative reagents. Hycult Biotech has been ISO-9001 certified since 1998 and we upgraded our certification to ISO-13485 in 2007, with a milestone of our first release of CE marked assays in 2009. Our vision, knowledgeable team and quality management system guarantee products of the highest grade combined with excellent technical service.